Results 201 to 210 of about 9,371 (304)
TRIPS, pharmaceutical patents, and generic competition in India. [PDF]
Kyle MK, Sampat BN, Shadlen KC.
europepmc +1 more source
The psychosocial toll of Dublin III on asylum seekers in the Netherlands
Abstract The Dublin III Regulation determines which EU Member State is responsible for examining asylum claims, but its implementation carries significant consequences for those subjected to it. This study examines how Dublin III, as implemented in the Netherlands, affects asylum seekers' psychosocial wellbeing using Silove′s Adaptation and Development
Imen El Amouri
wiley +1 more source
Compulsory licensing of pharmaceuticals during public health crisis: a TRIPS framework analysis. [PDF]
Li Z, Guo P.
europepmc +1 more source
Abstract In Canada, precarious migration is largely invisibilized. Nonetheless, b/ordering greatly affects people's realities by limiting access to social rights. In Quebec, migrants with precarious status (MPS) do not have access to healthcare, although Quebec has a “universal” healthcare coverage.
Émilie Pigeon‐Gagné +3 more
wiley +1 more source
Intellectual Property Protection of New Animal Breeds in China: Theoretical Justification, International Comparison, and Institutional Construction. [PDF]
Zhang W, Chen X.
europepmc +1 more source
Strategic Under-utilization of Patents and Entry Deterrence: The Case of Pharmaceutical Industry
This paper seeks to explain why some pharmaceutical companies are observed to withdraw their products before patents are expired and simultaneously introduce new patented (competing) products.
Kabiraj, Tarun +2 more
core
ABSTRACT Limited data exist on how patients and physicians perceive immune thrombocytopenia (ITP) symptoms and treatment‐related burden. I‐WISh (ITP World Impact Survey) 2.0 surveyed 1018 patients and 431 physicians in 15 countries to characterize the impact of ITP and its treatments on patients.
Nichola Cooper +17 more
wiley +1 more source
Characteristics of the Stem Cell Intellectual Property Rights and Patent Status: Focusing on Papers and Clinical Trials. [PDF]
Kim GJ, Kim Y, Shin WJ, Jeon Y.
europepmc +1 more source
ABSTRACT Exagamglogene autotemcel (exa‐cel) is a one‐time, ex vivo, CRISPR‐Cas9 gene edited cell therapy approved for patients with transfusion dependent β‐thalassemia (TDT) aged 12–35 years. In a Phase 3 study (CLIMB THAL‐111), exa‐cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion ...
Sujit Sheth +25 more
wiley +1 more source
Can knowledge reclassification accelerate technological innovation? [PDF]
Persoon P.
europepmc +1 more source

